Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national distribution agreement with Solo-Dex, Inc. for its continuous nerve block catheters, enhancing acute pain management capabilities. This technology allows anesthesiologists to insert catheters in two to three minutes for major procedures, potentially improving patient recovery while reducing reliance on opioids. The collaboration is aimed at capturing a significantly larger market, estimated to be ten times the current nerve catheter market. The joint effort aims to establish a new standard of care in pain management.

InfuSystem Holdings reported financial results for 2021, with net revenues at $102.4 million, a 5% increase from 2020. The fourth quarter saw revenues of $26.5 million, up 7.3% year-over-year. Despite this growth, net income dropped to $0.4 million, significantly lower than $10.7 million in Q4 2020. The gross margin decreased to 57.7%. Management anticipates 20% revenue growth in 2022, driven by pain management and a pending biomedical services contract expected to add $8-$12 million in revenue.

InfuSystem Holdings (NYSE: INFU) will announce preliminary fourth quarter and full year 2021 financial results on February 10, 2022, before the market opens. A conference call will follow the announcement at 9:00 a.m. Eastern Time to discuss these results. The company specializes in facilitating outpatient care for durable medical equipment through its Integrated Therapy Services and Durable Medical Equipment Services platforms. Interested parties can participate via phone or listen through a live webcast on the company’s investor relations website.

InfuSystem Holdings, Inc. (NYSE American: INFU) will present at the Sidoti Winter Virtual Investor Conference on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance, will lead the presentation.

A webcast will be available on their website, and a replay will follow the event. Investors can also engage in one-on-one meetings by contacting Lytham Partners.

InfuSystem Holdings (NYSE American: INFU) reported third-quarter 2021 net revenues of $26.6 million, a 6% increase year-over-year. The company anticipates $14-15 million in annual revenue from a new biomedical services contract, alongside growth in Pain Management services. Despite a net loss of $0.4 million and a 27% decline in Adjusted EBITDA, management is optimistic about future growth, reaffirming full-year revenue guidance of $107-110 million. Operating cash flow increased by 15% to $14.6 million.

InfuSystem Holdings, Inc. will release its Q3 2021 financial results on November 15, 2021, before market opens. A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Interested parties can participate by calling (833) 366-1127 or through a live webcast available on the company’s website. InfuSystem is a leading provider of health care services, focusing on integrated therapy services and durable medical equipment.

InfuSystem Holdings, Inc. (NYSE American: INFU) has entered into an exclusive three-year agreement with a major U.S. health care provider to offer its InfuBLOCK pain management therapy. This service includes electronic infusion pumps for post-surgical pain management, a 24/7 clinical hotline, and biomedical services. The agreement is expected to drive future revenue, leveraging InfuSystem’s expertise in outpatient care. The company emphasizes its non-narcotic pain management approach, aiming to enhance patient satisfaction while avoiding opioid-related risks.

InfuSystem Holdings (NYSE: INFU) announced its participation in Lake Street Capital Markets’ 5th Annual Best Ideas Growth (BIG5) Conference on September 14, 2021. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors during the event. This invitation-only virtual conference features executive presentations from around 100 public growth companies and connects them with top institutional investors nationwide. InfuSystem provides outpatient care through Integrated Therapy Services and Durable Medical Equipment Services.

InfuSystem Holdings, Inc. (INFU) reported a Q2 2021 net revenue of $24.8 million, down 4% from the prior year. However, ITS segment revenue increased 5% to $16.3 million. Gross profit decreased 6% to $15.1 million, with a gross margin of 60.6%. Net income was $0.8 million, or $0.04/share, compared to $4.1 million or $0.19/share in Q2 2020. The company announced a $20 million stock repurchase program and revised its 2021 guidance to lower end estimates of $107 million to $110 million in net revenues.